Barcelona <scp>Bio‐HF</scp> calculator version 3.0: recalibration and incorporation of sodium–glucose cotransporter 2 inhibitor treatment

Codina, Pau; Lupón, Josep; Subirana, Isaac; Zamora, Elisabet; Domingo, Mar; Santiago‐Vacas, Evelyn; Cediel, Germán; Borrellas, Andrea; Barallat, Jaume; Bayés‐Genís, Antoni

doi:10.1002/ejhf.2752

Cited by 4 publications

(6 citation statements)

References 5 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We read with attention the letter of Patoulias and Fragakis regarding our work 1 and we fully agree that fragility or frailty is an important facet in patients with heart failure (HF). We already reported the high prevalence 2 and relevance of fragility in such patients, both relative to prognosis 3 and quality of life.…”

Section: Reply To 'The Frail Patient and The Frailing Heart'mentioning

confidence: 79%

Reply to ‘The frail patient and the frailing heart’

Codina

Zamora

Bayés‐Genís

2023

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

Section: Reply To 'The Frail Patient and The Frailing Heart'mentioning

confidence: 79%

Reply to ‘The frail patient and the frailing heart’

Codina

Zamora

Bayés‐Genís

2023

European J of Heart Fail

Self Cite

View full text Add to dashboard Cite

“…inhibitors [18]. In cohorts evaluating the new versions of BCN calculator, the prognostic power (AUC) of BCN ranged from 0.825 to 0.860 for one-year all-cause mortality [17,18].…”

Section: Discussionmentioning

confidence: 99%

The Barcelona Bio-Heart Failure Risk Calculator may predict one-year mortality in patients with advanced heart failure

Szczurek-Wasilewicz,

Skrzypek,

Karmański

et al. 2024

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

In this single-center study, we found that a new prognostic scale, the Barcelona Bio-Heart Failure Risk Calculator (BCN), performs significantly better than traditional prognostic scores, such as the Heart Failure Survival Score (HFSS) and the Seattle Heart Failure Model (SHFM), in patients with end-stage heart failure. Lower BCN and HFSS scores are independently associated with a higher risk of one-year mortality in the analyzed population.

show abstract

“…In the present study, we aimed to assess mortality prediction performance of the Meta-Analysis Global Group in Chronic HF (MAGGIC-HF) risk score and the model of the Barcelona Bio-HF Risk Calculator (BCN-Bio-HF) containing N terminal pro brain natriuretic peptide (NT-proBNP) in HF patients receiving intermittent inotropic support with levosimendan as destination therapy. [10][11][12] Other scores, such as the Heart Failure Survival and SHFM could not be used in the present study due to lack of some important variables included in these calculators.…”

Section: Introductionmentioning

confidence: 99%

“…In the present study, we aimed to assess mortality prediction performance of the Meta‐Analysis Global Group in Chronic HF (MAGGIC‐HF) risk score and the model of the Barcelona Bio‐HF Risk Calculator (BCN‐Bio‐HF) containing N terminal pro brain natriuretic peptide (NT‐proBNP) in HF patients receiving intermittent inotropic support with levosimendan as destination therapy. 10 , 11 , 12 …”

Section: Introductionmentioning

confidence: 99%

Heart failure risk scores in advanced heart failure patients: insights from the LEVO‐D registry

et al. 2023

Self Cite

View full text Add to dashboard Cite

AimsThe prevalence of advanced heart failure (HF) is increasing due to the growing number of patients with HF and their better treatment and survival. There is a scarcity of data on the accuracy of HF web‐based risk scores in this selected population.This study aimed to assess mortality prediction performance of the Meta‐Analysis Global Group in Chronic HF (MAGGIC‐HF) risk score and the model of the Barcelona Bio‐HF Risk Calculator (BCN‐Bio‐HF) containing N terminal pro brain natriuretic peptide in HF patients receiving intermittent inotropic support with levosimendan as destination therapy.Methods and resultsFour hundred and three advanced HF patients from 23 tertiary hospitals in Spain receiving intermittent inotropic support with levosimendan as destination therapy were included. Discrimination for all‐cause mortality was compared by area under the curve (AUC) and Harrell's C‐statistic at 1 year. Calibration was assessed by calibration plots comparing observed versus expected events based on estimated risk by each calculator. The included patients were predominantly men, aged 71.5 [interquartile range 64–78] years, with reduced left ventricular ejection fraction (27.5 ± 9.4%); ischaemic heart disease was the most prevalent aetiology (52.5%). Death rate at 1 year was 26.8%, while the predicted 1‐year mortality by BCN‐Bio‐HF and MAGGIC‐HF was 17.0% and 22.1%, respectively. BCN‐Bio‐HF AUC was 0.66 (Harrell's C‐statistic 0.64), and MAGGIC‐HF AUC was 0.62 (Harrell's C‐statistic 0.61).ConclusionsThe two evaluated risk scores showed suboptimal discrimination and calibration with an underestimation of risk in advanced HF patients receiving levosimendan as destination therapy. There is a need for specific scores for advanced HF.

show abstract

Barcelona Bio‐HF calculator version 3.0: recalibration and incorporation of sodium–glucose cotransporter 2 inhibitor treatment

Cited by 4 publications

References 5 publications

Reply to ‘The frail patient and the frailing heart’

Reply to ‘The frail patient and the frailing heart’

The Barcelona Bio-Heart Failure Risk Calculator may predict one-year mortality in patients with advanced heart failure

Heart failure risk scores in advanced heart failure patients: insights from the LEVO‐D registry

Contact Info

Product

Resources

About